Forty years of Intermountain patient records — clinical, omics, tissue, and claims — organized for discovery partnerships.
Culmination Bio
venture dormant confidence: Medium status: Draft updated 2026-08-11
Summary
Culmination Bio is described as a biotech company connected to Intermountain Health. Drug discovery fails often because early biological hypotheses are wrong.
Impact
Drug discovery fails often because early biological hypotheses are wrong. Culmination has described a longitudinal clinical-data and tissue asset, but the existing raw capture is unusable and does not support the earlier scale figures.
Without a dedicated spinout, much of this data could remain siloed inside the health system. A reported Merck collaboration may provide a partnership template, but its duration is not established by captured evidence.
What They Are Building
Culmination builds a searchable data platform rather than drugs directly. Discovery Cohort data is organized in Apex, the company's Intelligence Platform, where partners can query disease summaries, diagnosis counts and types, demographics, prescriptions, and patient-specific genomic overviews, then assemble custom cohorts.
The hard engineering problems sit in de-identification, record linkage, identity resolution across decades of heterogeneous EHR coding, and maintaining HIPAA and IRB compliance while preserving research utility. Linking clinical records to omics and tissue samples longitudinally requires infrastructure most health systems have not built at this scale.
What They Need Now
Likely needs include computational biologists, clinical data scientists, bioinformaticians, health-data engineers, privacy and compliance specialists, IRB and regulatory experts, and pharma business-development leaders who understand data-licensing deals. The Intermountain parent brings institutional scale; the spinout structure is meant to move faster than a hospital QI program.
Who Could Help
Useful helpers include health-data privacy counsel, IRB and clinical-research compliance advisors, pharma partnership strategists, bioinformatics platform engineers, and investors with experience in real-world-evidence and data-platform businesses.
Utah Context
Culmination extends a long Utah thread in health-data infrastructure. Intermountain's clinical quality-improvement work showed how an integrated regional system could treat care delivery as an engineering problem; Culmination applies a different commercial lens to the same institutional data advantage.
The spinout also sits near Utah's broader life-sciences cluster — companies such as Myriad Genetics, BioFire Diagnostics, and Huntsman Cancer Institute — though Culmination's model is platform licensing rather than diagnostic kits or therapeutic development.
Evidence
See Also
- Intermountain Clinical Quality Improvement — historical Intermountain delivery-science work that shares the parent health system's data-and-process culture.
- Myriad Genetics — Utah molecular diagnostics company; adjacent life-sciences context.
- Huntsman Cancer Institute — major Utah oncology research institution.
Open Questions
- culmination.com does not resolve (NXDOMAIN as of 2026-07-14) — Website points at the Intermountain Health page until the company domain returns; no careers board located.
- Which partnership terms, cohort sizes, and hypothesis-validation outcomes from Merck, Amgen, or other pharma collaborators are publicly verifiable?
- How representative is Intermountain's Intermountain West patient population for generalizable drug-discovery use cases, especially for population-specific biology?
- What governance constraints does Intermountain Health's nonprofit parent place on Culmination's commercial independence?
- What primary evidence establishes the terms and extent of Intermountain, Amgen, and Merck backing?